Research Expertise:

• Has been Principal Investigators (PI) in Federal and Pharmaceutical studies of Affective disorders and Women`s Mental Health and disorders.

Grants and Sponsored Research:

• January 2005–January 2008
  A multicenter, randomized, double-blind, placebo- controlled study of the safety and efficacy of Arpiprazole as adjunctive therapy in the treatment of patients with major depressive disorder
  Bristol Myers Squibb Co.
  Role: Co-Investigator
  
• January 2004–January 2008
  Olanzapine vs. Aripiprazole in the treatment of acutely ill patients with schizophrenia
  Eli Lilly and Company
  Role: Co-Investigator
  
• January 2002–January 2008
  Identification and diagnosis of mental disorders in Beijing Ob/Gyn clinics
  Pfizer Inc. Foundation
  Role: Co-Investigator
  
• January 2005–January 2007
  Diagnosis of clinically relevant premenstrual syndromes- Achieving international interdisciplinary consensus for update of ICD-10 Diagnosis of PMS
  Schering Inc.
  Role: Co-Investigator
  
• January 2005–January 2007
  A randomized, double-blind, placebo-controlled, parallel group study of the safety and efficacy of three dose levels of CORLUX (Mifepristone) plus an antidepressant vs. placebo plus and antidepressant in the treatment of psychotic symptoms in patients with PMS.
  Corcept
  Role: Principal Investigator
  
• January 2002–January 2003
  Phase III, open label, multicenter, multinational, contraceptive study of Medroxyprogesterone Acetate (MPA: mg) and Estradiol Cypionate (E2C 5 mg) injectable suspension administered subcutaneously
  Pharmacia
  Role: Co-Investigator
  
• January 2001–January 2003
  The Relationship between Valproate and Other Mood-Stabilizer Therapies to the Polycystic Ovarian Syndrome and Polycystic Ovarian Morphology in Women with Bipolar Disorder
  Harvard Medical School
  Role: Co-Investigator
  
• January 1999–January 2003
  Beijing Double Blind Placebo Controlled Trial Comparing Fluoxetine to Electro-Acupuncture
  Eli Lilly and Company
  Role: Co-Investigator
  
• January 1999–January 2003
  A Comparative Study of the Steady-State Pharmacokinetics of Lithium Before and During Multiple Oral Daily Topiramate Dosing in patients with Bipolar Disorder
  R.W. Johnson
  Role: Co-Investigator
  
• January 2001–January 2002
  Systemic Treatment Enhancement Program for Bipolar Disorder
  Role: Principal Investigator
  
• January 2001–January 2002
  Phase IIIB Multi center trial, a comparison of Lunelle and Depo-Provera on Bone Mineral Density
  Pharmacia
  Role: Co-Investigator
  
• January 2000–January 2002
  A randomized, placebo-controlled, double blind study of Naltrel in promotion of abstinence among alcohol dependent subjects
  Drug Abuse Science
  Role: Co-Investigator
  
• January 1999–January 2002
  Systematic Treatment Enhancement Program for Bipolar Disorder
  National Institute of Mental Health
  Role: Principal Investigator
  
• January 1999–January 2002
  Risperidone Depot (Microspheres) in the treatment of Subjects with Schizophrenia and Schizoaffective Disorder
  Janssen
  Role: Co-Investigator
  
• January 1998–January 2002
  A double blind, randomized, placebo and historical controlled study of the safety and efficacy of premarin/trimegestrone for post menopausal hormone replacement therapy
  Wyeth Ayerst Research
  Role: Co-Investigator
  
• January 1999–January 2001
  Olanzapine Alone & in Combination with Fluoxetine vs. Placebo in Major Depressive Disorder with Psychotic Features
  Eli Lilly and Company
  Role: Co-Investigator
  
• January 1999–January 2001
  Study of St. John's Wart on Outpatients with DSM-IV Major Depression
  Vanderbilt Research University
  Role: Co-Investigator
  
• January 1998–January 2001
  Intermittent Dosing of Fluoxetine in the Treatment of Premenstrual Dysphoric Disorder: Late Luteal Phase Daily Dosing Versus Placebo
  Eli Lilly and Company
  Role: Co-Investigator
  
• January 1999–January 2000
  Open Label Reboxetine Rescue and Continuation Therapy
  Pharmacia Upjohn
  Role: Co-Investigator
  
• January 1999–January 2000
  Pharmacogenomics Blood Sampling Protocol
  Pharmacia Upjohn
  Role: Co-Investigator
  
• January 1999–January 2000
  Reboxetine vs. Placebo in the treatment of Major Depressive Disorder Resistant to Fluoxetine
  Pharmacia Upjohn
  Role: Co-Investigator
  
• January 1998–January 2000
  Olanzapine in the Reduction of Hyperprolactinemia
  Eli Lilly and Company
  Role: Co-Investigator
  
• January 1996–January 2000
  Double-Blinded Parallel Comparison of Luteal Phase Treatment with Sertraline and Placebo in Patients with Premenstrual Dysphoric Disorder
  Pfizer, Inc.
  Role: Co-Investigator
  
• January 1997–January 1998
  Reboxetine versus Placebo in the treatment of Major Depressive Disorder
  Pharmacia Upjohn
  Role: Co-Investigator
  
• January 1996–January 1998
  A Ten-Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Oral CP-93,393-1 in outpatients with Major Depressive Disorder
  Role: Co-Investigator
  
• January 1993–January 1997
  Treatment of dysphoric menstrual syndromes with mifepristone (RU-486)
  Rousel Uclaf
  Role: Co-Investigator
  
• January 1995–January 1996
  Intermittent late luteal treatment with sertraline of women with dysphoric PMS-- A Pilot Study
  Role: Co-Investigator
  
• January 1995–January 1996
  Fifty -two week, open label, randomized study evaluating the safety and efficacy of oral ziprasidone (CP-88-059-1) 40-80 mg, bid and risperidone (3-5 mg daily) in the maintenance treatment of outpatients with schizophrenia or schizo-affective disorder
  Role: Co-Investigator
  
• January 1994–January 1996
  Sertraline (Placebo controlled, double blind) for treatment of women with dysphoric premenstrual syndrome
  Pfizer Inc., U.S. Pharmaceutical Group
  Role: Co-Investigator
  
• September 1991–August 1995
  Alpha 2 Receptors, Luteal Depression and Gonadal Hormones
  National Institute of Mental Health
  Role: Principal Investigator
  $518,074
• June 1990–April 1994
  Menstrually Related Changes in Cognitive Functions
  National Institute of Mental Health
  Role: Principal Investigator
  $101,869
• January 1994–January 1994
  Welbutrin sustained release form, as treatment for major depressive disorders
  Burroughs Wellcome Co.
  Role: Co-Investigator
  
• January 1994–January 1994
  Assessment of Mood and Cognition in Woman with Breast Cancer
  Nathan Cummings Foundation
  Role: Co-Investigator
  
• January 1993–January 1994
  Double blind follow-up comparison of sertraline, imipramine and placebo in patients with dysthymic disorder
  Pfizer Inc., U.S. Pharmaceutical Group
  Role: Co-Investigator
  
• January 1992–January 1993
  Double blind parallel comparison of sertraline, imipramine and placebo in outpatients with Dysthymia
  Pfizer Inc., U.S. Pharmaceutical Group
  Role: Co-Investigator
  
• January 1992–January 1993
  Luproid acetate depot for treatment of dysphoric PMS
  TAP Pharmaceuticals, Inc.
  Role: Co-Investigator
  
• January 1991–January 1993
  Estraderm patches as treatment of dysphoric PMS, an their influence on cognitive functions and the Imidazoline- CDS system
  Ciba Geigi Co.
  Role: Co-Investigator
  
• January 1992–January 1992
  Abecarnil (Placebo Controlled, low and high dose) for treatment of outpatients with Generalized Anxiety disorder
  Sandoz Pharmaceuticals Corp.
  Role: Co-Investigator
  
• January 1991–January 1991
  Drug Induced Osteoporosis and Behavioral Changes
  Research for Health in Erie County
  Role: Co-Investigator
  
• January 1990–January 1991
  Hormonal Modulation of Brain and Behavior
  RGK Foundation
  Role: Co-Investigator
  
• January 1989–January 1990
  Hormonal Modulation of Brain and Behavior
  Daniel Roblins Memorial Fund
  Role: Co-Investigator
  
• January 1989–January 1989
  The Use of Hydrochlorothiazide for Premenstrual Edema
  Bristol Myers Squibb Co.
  Role: Co-Investigator
  
• January 1987–January 1989
  Administrative Structure for Brain & Behavioral Research
  National Institute of Mental Heath
  Role: Principal Investigator
  
• January 1985–January 1989
  The Desipramine Cortisol Test in Depression
  National Institute of Mental Health
  Role: Co-Investigator
  
• January 1987–January 1988
  Clinical Study of Bupropion in Depression
  Burroughs Wellcome Co.
  Role: Co-Investigator
  
• January 1985–January 1988
  Biological Studies of Depression
  SUNY- Biomedical Research
  Role: Principal Investigator
  
• January 1987–January 1987
  Biology of Aberrant Behavior
  Bernice P. Roger's Trust
  Role: Co-Investigator
  
• January 1985–January 1987
  Cortisol, MHPG and Depression
  National Institute of Mental Health
  Role: Principal Investigator
  
• January 1981–January 1986
  Premenstrual Syndromes: Biological and Diagnostic
  National Institute of Mental Health
  Role: Co-Principal Investigator
  
• January 1985–January 1985
  Preliminary Studies of Tardive Dyskinesia
  The Ritter's Foundation
  Role: Co-Investigator
  
• January 1982–January 1985
  Cortisol Secretion and Depression: A New Test
  National Institute of Mental Health
  Role: Principal Investigator
  
• January 1983–January 1984
  The Prolactin Response to Reserpine in Schizophrenia
  National Institute of Mental Health
  Role: Co-Investigator
  
• January 1983–January 1984
  Biology of Affective Disorders and Schizophrenia
  The Ritter's Foundation
  Role: Co-Investigator
  
• January 1982–January 1982
  Biology of Affective Disorders and Premenstrual Changes
  The Ritter's Foundation
  Role: Co-Investigator
  
• January 1982–January 1982
  Research in Biological Psychiatry
  Richard Hirschfeld‘s Bequest
  Role: Co-Investigator
  $248,000
• January 1982–January 1982
  The Dean's Discretionary Fund
  Richard Hirschfeld‘s Bequest
  Role: Co-Investigator
  $164,000
• January 1980–January 1981
  Endocrinology of Mental Disorders
  SUNY- Biomedical Research Grant
  Role: Principal Investigator
  
• January 2005
  A multicenter, randomized, double-blind, placebo- controlled study of a combination of levonorgestrel and ethinyl estradiol in a continuous daily regimen in subjects with premenstrual dysphoric disorder
  Wyeth Ayerst Research
  Role: Co-Investigator
  
• January 1994
  2nd International Congress of Women's Mental Health
  2nd International Congress of Women's Mental Health
  Role: Co-Investigator
  $811,170
• Prevalence of Hyperprolactinemia in Schizophrenic Patients Treated with Antipsychotic Drugs
  Eli Lilly and Company
  Role: Co-Investigator